A case of severe interstitial pneumonitis probably caused by imatinib mesylate in a patient with gastrointestinal stromal tumor
-
- Tateishi Yoshihisa
- Department of Surgery, Chosei Public Hospital
-
- Abe Yasuhisa
- Department of Surgery, Chosei Public Hospital
-
- Sasagawa Shinichi
- Department of Surgery, Chosei Public Hospital
-
- Sashiyama Hiroshi
- Department of Surgery, Chosei Public Hospital
-
- Mamiya Toshitaka
- Department of Surgery, Chosei Public Hospital
-
- Hirasawa Hiroyuki
- Department of Emergency and Critical Care Medicine, Graduate School of Medicine, Chiba University
-
- Oda Shigeto
- Department of Emergency and Critical Care Medicine, Graduate School of Medicine, Chiba University
Bibliographic Information
- Other Title
-
- メシル酸イマチニブの関与が強く疑われた急性間質性肺炎の1例
Search this article
Abstract
An 82-year-old man who had advanced gastrointestinal stromal tumor (GIST) received chemotherapy with imatinib mesylate. CT scan showed remarkable tumor shrinkage after 2 weeks of the treatment and the treatment was continued. He developed, however, exertional dyspnea and cough after 35 days of the therapy with the agent. Three days after the onset of those symptoms, marked hypoxemia and bilateral interstitial filtrate on chest CT examination appeared and he was hospitalized. The diagnosis of drug-induced pneumonitis was strongly suggested, so that the agent was discontinued. He received mechanical ventilation for 6 days and corticosteroid therapy consisting of methylprednisolone (1g·day-1) for 3 days, followed by administration of prednisolone. These treatments were effective for respiratory failure and they achieved almost complete recovery from the respiratory failure symptomatically and radiographically. These findings suggested that the patient had drug-induced interstitial pneumonitis caused by imatinib mesylate. Imatinib mesylate was restarted with steroid subsequently and he is now in good health. Although there are several reported cases of interstitial pneumonitis by imatinib mesylate as far as we know, careful attention must be taken for the early identification of such adverse effect during imatinib mesylate therapy.
Journal
-
- Journal of the Japanese Society of Intensive Care Medicine
-
Journal of the Japanese Society of Intensive Care Medicine 13 (2), 145-149, 2006
The Japanese Society of Intensive Care Medicine
- Tweet
Keywords
Details 詳細情報について
-
- CRID
- 1390282679421493376
-
- NII Article ID
- 130003641456
- 10018810893
-
- NII Book ID
- AN10474053
-
- ISSN
- 1882966X
- 13407988
-
- Text Lang
- ja
-
- Data Source
-
- JaLC
- Crossref
- CiNii Articles
-
- Abstract License Flag
- Disallowed